{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-004570","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2024-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.723166+00:00","generated_at":"2026-06-04T03:40:08.021498+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NRx Pharma 2023 net loss $30.2M; expects top-line data this month for NRX-101 TRBD trial","bullets":["Net loss for full-year 2023: $30.2M vs $39.8M in 2022; Q4 2023 loss $4.3M vs $10.2M in Q4 2022.","Cash $4.6M at Dec 31, 2023; added $8M in Q1 2024 via equity sales and $5.1M milestone from Alvogen/Lotus.","Expects top-line data in April 2024 from Phase 2b/3 trial of NRX-101 in TRBD; achieved 94% rater concordance.","Plans to spin out HOPE Therapeutics for IV Ketamine; NDA filing expected by June 2024; term sheets for $60M investment.","Reduced G&A expenses 50% YoY to $14.2M in 2023 from $27.3M; corporate overhead decreased by half."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-004570","json":"https://secwatch.observer/filing/0001558370-24-004570.json","markdown":"https://secwatch.observer/filing/0001558370-24-004570.md","text":"https://secwatch.observer/filing/0001558370-24-004570.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000155837024004570/0001558370-24-004570-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000155837024004570/nrxp-20240401x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:40:08.021498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1c210163f676cd24c3e1f32b39dae2339512db3","claim":"NRX Pharmaceuticals, Inc. reported financial results for the fourth fiscal quarter and year ending December 31, 2023.","evidence_excerpt":"On April 1, 2024, NRx Pharmaceuticals, Inc. issued a press release announcing its financial results for the fourth fiscal quarter and year ending December 31, 2023 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000155837024004570/0001558370-24-004570-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth fiscal quarter and year ending December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}